Metastatic Breast Cancer:
How Molecular Profiling Revealed a PIK3CA Pathway

This article is a de-identified educational case review. It describes the clinical course of one patient managed at Beijing Arion Cancer Hospital and reflects the team's approach to treatment-resistant metastatic breast cancer. It is not medical advice, nor does it guarantee outcomes for other patients. Treatment decisions must be individualized by qualified physicians.

Case Overview: When the Disease Returned

In early 2024, a 49-year-old woman was brought to Beijing Arion Cancer Hospital with rapidly worsening metastatic breast cancer. She had undergone breast surgery in 2021, but had stopped adjuvant medication on her own and did not return for surveillance. By the time she arrived, the disease had spread extensively: the left breast was ulcerated and draining, a large pleural effusion was compressing her lung, and imaging showed bone metastases throughout the pelvis and spine.

Her medical team performed emergency thoracentesis, draining more than one liter of fluid, which allowed her to breathe more easily. A multidisciplinary tumor board then formulated a treatment plan. Initial systemic therapy produced a noticeable response, and she was discharged after about three weeks. Follow-up imaging several months later looked encouraging.

A Pattern of Short-Lived Responses

The improvement did not last. In 2025, new liver lesions appeared. The team switched to trastuzumab deruxtecan (T-DXd), a modern antibody–drug conjugate used in selected HER2-low or HER2-positive breast cancers. The disease stabilized for roughly eight months. Capecitabine was tried next, without success. Nab-paclitaxel produced some improvement in chest-wall disease but did not control the liver.

Each regimen worked for a time, yet resistance developed quickly — in one instance within two months. The repeated cycles of response and relapse took a physical and emotional toll. At one point, the patient told her physician that she wanted to stop treatment and go home.

The Pivot to Molecular Profiling

After multiple lines of therapy failed, the MDT suspected that the explanation lay in the tumor's biology rather than in drug selection alone. The question was whether an actionable genomic alteration was driving the rapid resistance. Comprehensive next-generation sequencing (NGS) of the tumor was recommended.

While awaiting results, the team used a bridging endocrine-based regimen combined with a CDK4/6 inhibitor to try to slow progression without further compromising the patient's already impaired liver function. Whole-liver radiation was considered inappropriate because her liver could not tolerate it.

The sequencing report identified a PIK3CA mutation, an alteration present in a subset of hormone receptor–positive, HER2-negative breast cancers. PIK3CA mutations activate the PI3K/AKT/mTOR pathway, which can drive endocrine resistance and rapid progression. Identifying this alteration shifted the discussion toward PI3K-targeted therapy.

Why This Case Matters

This case illustrates several principles relevant to modern breast oncology:

• Resistance is not always random. When several agents fail in quick succession, tumor biology — including acquired or intrinsic genomic alterations — may be the dominant factor.
• Molecular profiling can redirect care. In selected patients, identifying a driver mutation such as PIK3CA opens the door to targeted agents that address the underlying signaling pathway.
• MDT coordination protects patients through transitions. Serial tumor boards adjusted the plan at each inflection point, including bridging therapy while awaiting genomic results.
• Adherence and surveillance matter. Stopping adjuvant therapy and missing follow-up visits allowed the disease to progress silently before becoming symptomatic.

About PIK3CA and Targeted Options

PIK3CA is one of the most commonly mutated oncogenes in hormone receptor–positive, HER2-negative breast cancer. When mutated, it can promote cell growth and survival, contributing to endocrine therapy resistance. In selected postmenopausal women or men with PIK3CA-mutated disease that has progressed on endocrine therapy, PI3K inhibitors combined with endocrine therapy have been evaluated in clinical trials and approved in some jurisdictions.

Availability, reimbursement, and eligibility criteria differ by country and by hospital. Not every PIK3CA mutation is clinically actionable, and not every patient is a candidate for targeted therapy. The decision to use any targeted agent requires review by an experienced oncology team.

Key Takeaways

• Metastatic breast cancer that progresses through multiple lines of therapy warrants reconsideration of the tumor's molecular drivers.
• Comprehensive genomic profiling may identify actionable alterations such as PIK3CA mutations that change the therapeutic strategy.
• Bridging therapy and organ-function assessment are essential when patients are too unwell for immediate aggressive treatment.
• Every patient's situation is unique; treatment plans must be individualized by an experienced oncology team.